🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

86+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 86 recruiting trials for “myasthenia-gravis

NARecruitingNCT05564936

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

🏥 Ad scientiam📍 19 sites📅 Started Jan 2024View details ↗
RecruitingNCT06299748

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

🏥 argenx📍 4 sites📅 Started Nov 2023View details ↗
RecruitingNCT07146425

Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis

👨‍⚕️ Chongbo Zhao, Ph.D., Huashan Hospital📍 1 site📅 Started Aug 2023View details ↗
RecruitingNCT06006832

A Prospective Cohort Study of Myasthenia Gravis in China

👨‍⚕️ Yuzhou Guan, Peking Union Medical College Hospital📍 1 site📅 Started Aug 2023View details ↗
NARecruitingNCT06064695

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

👨‍⚕️ Kristina M Kelly, DPT, University of Missouri-Columbia📍 2 sites📅 Started Jul 2023View details ↗
Phase 3RecruitingNCT06587867

Seronegative Myasthenia Gravis - Efgartigimod IV

👨‍⚕️ Vera Bril, MD, Toronto General Hospital📍 1 site📅 Started Jun 2023View details ↗
Phase 1RecruitingNCT05828225

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

👨‍⚕️ He Huang, MD, Zhejiang University📍 1 site📅 Started Apr 2023View details ↗
NARecruitingNCT06879210

Application of Artificial Intelligence in Precision Medicine and Healthcare

🏥 Yi Ting Yeh📍 1 site📅 Started Apr 2023View details ↗
NARecruitingNCT06754020

TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls

🏥 Yi Ting Yeh📍 1 site📅 Started Jan 2023View details ↗
Phase 2, PHASE3Enrolling by InvitationNCT05374590

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

🏥 argenx📍 16 sites📅 Started Aug 2022View details ↗
Phase 2RecruitingNCT05067348

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

👨‍⚕️ Ting Chang, MD,PHD, The Second Affiliated Hospital of Air Force Medical University📍 6 sites📅 Started Jul 2022View details ↗
Phase 2, PHASE3RecruitingNCT05265273

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

👨‍⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 19 sites📅 Started Jul 2022View details ↗
NARecruitingNCT06881173

The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis

👨‍⚕️ Ju-Han Liu, project leader📍 1 site📅 Started Jun 2022View details ↗
RecruitingNCT05337891

Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis

👨‍⚕️ Jakub M Antczak, MD, Jagiellonian University Medical College, Department of Neurology📍 1 site📅 Started Jun 2022View details ↗
Phase 3RecruitingNCT05868837

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

👨‍⚕️ Raffaele Iorio, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Feb 2022View details ↗
RecruitingNCT05214612

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

🏥 Assiut University📍 1 site📅 Started Jan 2022View details ↗
Phase 2, PHASE3RecruitingNCT04833894

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

🏥 argenx📍 25 sites📅 Started Oct 2021View details ↗
Phase 3RecruitingNCT04951622

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

👨‍⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 112 sites📅 Started Jul 2021View details ↗
RecruitingNCT04837625

Study of Myasthenic Crisis in China

🏥 Huashan Hospital📍 1 site📅 Started Oct 2020View details ↗
EARLY_Phase 1RecruitingNCT04561557

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

👨‍⚕️ Wei Wang, MD, Tongji Hospital📍 1 site📅 Started Sep 2020View details ↗
← PreviousPage 4 of 5Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →